Article
Parallel Screening and Activity Profiling with HIV Protease Inhibitor Pharmacophore Models
Corresponding author addresses: Institute of Pharmacy, Department of Pharmaceutical Chemistry, Innrain 52c, University of Innsbruck, A-6020 Innsbruck, Austria (T.L.). Corresponding author phone: +43 512 507 5252; fax: +43 512 507 5269; e-mail: thierry.langer@uibk.ac.at. (T.L.) and e-mail: theodora.steindl@uibk.ac.at (T.M.S.).
University of Innsbruck and Center for Molecular Biosciences Innsbruck (CMBI).
Inte:Ligand GmbH.
Accelrys Inc.
Accelrys SARL, Parc Club Orsay Université.
Abstract

Parallel Screening has been introduced as an in silico method to predict the potential biological activities of compounds by screening them with a multitude of pharmacophore models. This study presents an early application example employing a Pipeline Pilot-based screening platform for automatic large-scale virtual activity profiling. An extensive set of HIV protease inhibitor pharmacophore models was used to screen a selection of active and inactive compounds. Furthermore, we aimed to address the usually critically eyed point, whether it is possible in a parallel screening system to differentiate between similar molecules/molecules acting on closely related proteins, and therefore we incorporated a collection of other protease inhibitors including aspartic protease inhibitors. The results of the screening experiments show a clear trend toward most extensive retrieval of known active ligands, followed by the general protease inhibitors and lowest recovery of inactive compounds.
View: Full Text HTML | Hi-Res PDF
Tools
-
Add to Favorites
-
Download Citation
-
Email a Colleague -
Permalink
Order Reprints
Rights & Permissions
Citation Alerts
Accession Codes
History
- Published In Issue March 26, 2007
- Received July 28, 2006
Cart


